How Rare is Morquio Syndrome (MPS IV)? Prevalence Stats

Morquio syndrome, or Mucopolysaccharidosis type IV (MPS IV), is an exceptionally rare genetic metabolic disorder. In this condition, the body lacks a specific enzyme needed to break down certain sugar chains (glycosaminoglycans), leading to their buildup and causing issues with bone development, joints, and organs. Overall, it is estimated to occur in roughly 1 in 200,000 to 1 in 300,000 births worldwide ^[1]. However, how often it appears depends heavily on where you live and your family background.

Morquio syndrome is an autosomal recessive condition. This means that for a child to be born with the syndrome, both parents must be carriers of the mutated gene.

Understanding the Two Subtypes: Type A vs. Type B

Morquio syndrome is divided into two distinct subtypes based on which specific enzyme is missing. Knowing your exact subtype is critical because it dictates your treatment options:

• Morquio Type A (MPS IVA): This is by far the most common form, accounting for the vast majority of diagnosed cases ^[1]. It is caused by a lack of the GALNS enzyme. Notably, there are specific, modern treatments available for Type A, such as Enzyme Replacement Therapy (ERT), designed to replace this missing enzyme.
• Morquio Type B (MPS IVB): This subtype is extremely rare, making up only a small fraction of individuals diagnosed with Morquio syndrome ^[1]. It involves a deficiency in a different enzyme (GLB1) and requires a different approach to care, as ERT for Type A will not work for Type B.

Regional Differences

The overall estimate of 1 in 200,000 to 300,000 is an average, but the actual birth prevalence (the number of babies born with the condition) varies dramatically across different countries.

• Higher prevalence regions: In some parts of the world, such as the United Arab Emirates and Northern Ireland, birth rates for Morquio A have been reported as high as 1 in 71,000 and 1 in 76,000, respectively ^[1]. Regions with higher rates of consanguinity (parents who are blood relatives) tend to have a higher incidence of the condition because both parents are more likely to carry the same recessive gene ^[1].
• Lower prevalence regions: In other nations, the condition is far less common. For instance, in Japan, the reported birth rate for Morquio A is roughly 1 in 500,000 ^[1].
• Unclassified rates: In some historical studies where Types A and B were not separated, researchers have reported rates as varied as 1 in 28,000 in Saudi Arabia to 1 in 208,000 in Denmark ^[1].

Birth Prevalence vs. Living with the Condition

When researching rare diseases, you might notice two different types of statistics: birth prevalence (how many babies are born with it) and point prevalence (how many people in a given population are living with it at any specific time).

Because Morquio syndrome is progressive and can impact life expectancy, the point prevalence is historically lower than the birth prevalence. For example, studies estimate that roughly 1 in 599,000 people in the UK and 1 in 1,872,000 people in Malaysia are currently living with Morquio A ^[1].

However, it is vital to remember that these statistics are based on historical data and do not predict your or your child’s specific future. Modern advancements in medical care, proactive symptom management, and targeted treatments are actively improving the quality of life and outcomes for many patients.

Because Morquio syndrome is so rare, building an experienced care team is crucial. Connecting with specialized medical centers and established patient advocacy groups—such as the National MPS Society—can provide invaluable support, up-to-date research, and a community that deeply understands your journey.